We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Find out more Skip to Main Content

Instructions to Authors

AIMS AND SCOPE
AUTHORS: ROLES AND RESPONSIBILITIES
TABLES
FIGURE PREPARATION
ABBREVIATIONS
TRADE NAMES
REFERENCES
SUPPLEMENTARY MATERIAL
COLOUR ILLUSTRATIONS
LANGUAGE EDITING
COPYRIGHT
THIRD-PARTY CONTENT IN OPEN ACCESS PAPERS
TRANSPARENCY DECLARATION
CROSSCHECK
PREPARATION OF MANUSCRIPTS TO BE PUBLISHED IN CKJ
LICENCES AND CHARGES
OFFPRINTS
AUTHOR SELF-ARCHIVING/PUBLIC ACCESS POLICY
EDITORIAL ENQUIRIES
PRODUCTION ENQUIRIES
CROSSREF FUNDING DATA REGISTRY
DISCLAIMER

Note to authors:

ALL ARTICLES MUST BE SUBMITTED ONLINE. Once you have prepared your manuscript according to the Instructions below, Please pay particular attention to the sections on Conflict of Interest Declaration and Figure Preparation.

When you are adding authors, please check first whether they already have an account before opening an account for them, by searching on their surname in the quick search. Only create a new account for an author if they are not already in the database. This will prevent duplicate accounts from building up which can make finding people difficult and is time-consuming and expensive to fix. Be aware that some people have more than one email so searching on email address does not always bring up the reviewer you are looking for.

Please visit http://mc.manuscriptcentral.com/ckj to submit to Clinical Kidney Journal (CKJ). Instructions on submitting your manuscript online can be viewed here.

AIMS AND SCOPE

Clinical Kidney Journal: Clinical and Translational Nephrology (ckj) , an official journal of the ERA-EDTA (European Renal Association-European Dialysis and Transplant Association), is a fully open access, online only journal publishing bimonthly. The journal is an essential educational and training resource integrating clinical, translational and educational research into clinical practice. ckj aims to contribute to a translational research culture among nephrologists and kidney pathologists that helps close the gap between basic researchers and practicing clinicians and promote sorely needed innovation in the Nephrology field. All research articles in this journal have undergone peer review.

Fees waived for articles published in ckj throughout 2017
There will be no charge to authors for open access publication throughout 2017, with the exception of those who must publish under a CC-BY licence in order to comply with funding body mandates.

CKJ publishes the following types of article:

• Editorial Comments
• CKJ Reviews
• CKJ Reviews Series - CKD hotspots around the World
• Original Articles
• Exceptional Cases
• Correspondence and Personal Opinion

CKJ only accepts online submission. Please visit Manuscript Central . You will also find more complete submission instructions at this site.

CKJ may consider publication of high-quality, peer reviewed supplements. Please contact supplements@oup.com in the first instance.

AUTHORS: ROLES AND RESPONSIBILITIES

Each author should have participated sufficiently in the work to take public responsibility for the content. This participation must include:

1. Conception or design, or analysis and interpretation of data, or both.
2. Drafting the article or revising it.
3. Providing intellectual content of critical importance to the work described.
4. Final approval of the version to be published. (See Br Med J 1985; 291: 722-723.)

Manuscripts should bear the full name and address, with telephone, fax, and email of the author to whom the proofs and correspondence should be sent (corresponding author). For all authors, first name and surname should be written in full.

In a covering letter, the individual contribution of each co-author must be detailed. This letter must contain the statement: 'the results presented in this paper have not been published previously in whole or part, except in abstract form'. Should your manuscript be accepted for publication, you will be required to give signed consent for publication (see copyright section).

On acceptance, the corresponding author will be advised of the approximate date of receipt of proofs. Proofs must be returned by the author within 48 hours of receipt.

To accelerate publication, only one set of PDF proofs is sent to the corresponding author by email. This shows the layout of the paper as it will appear in the Journal. It is, therefore, essential that manuscripts are submitted in their final form. Proof-reading must be limited to the correction of typographical errors. Any other changes involve time-consuming and expensive work and may not be permitted at this stage. If additions are necessary, these may be made at the end of the paper in a Note in Proof. Major changes may be subject to editorial approval.

Authors are referred to the statement on uniform requirements for manuscripts submitted to biomedical journals prepared by an international committee of medical journal editors. (Br Med J 1982; 284: 1766-1770, Ann Intern Med 1982; 96: 766-771.)

Protection of Human Subjects and Animals in Research
When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

Patient consent
Authors should state that in their paper that informed consent has been obtained from the subjects (or their guardians) as specified in the ICMJE Reccomendations

CKJ takes publication ethics very seriously. If misconduct is found or suspected after the manuscript is published, the journal will investigate the matter and this may result in the article subsequently being retracted.

Authors should observe high standards with respect to publication ethics as set out by the Commission on Publication Ethics (COPE) and International Committee of Medical Journal Editors (ICMJE) . Falsification or fabrication of data, plagiarism, including duplicate publication of the author's own work without proper citation, and misappropriation of the work are all unacceptable practices. Any cases of ethical misconduct are treated very seriously and will be dealt with in accordance with the COPE guidelines. If misconduct is found or suspected after the manuscript is published, the journal will investigate the matter and this may result in the article subsequently being retracted.

TABLES

All tables must be numbered consecutively and each must have a brief heading describing its contents. Any footnotes to tables should be indicated by superscript characters. Tables must be referred to in the main text in running order. All tables must be simple and not duplicate information given in the text.

FIGURE PREPARATION

Please be aware that the requirements for online submission and for reproduction in the journal are different: (i) for online submission and peer review, please upload your figures either embedded in the word processing file or separately as low-resolution images (.jpg, .tif, .gif or. eps); (ii) for reproduction in the journal, you will be required after acceptance to supply high-resolution .tif files (1200 d.p.i. for line drawings and 300 d.p.i. for colour and half-tone artwork). We advise that you create your high-resolution images first as these can be easily converted into low-resolution images for online submission.

We would encourage authors to generate line figures in colour using the following colour palette:

Blue (CMYK definition - 96/60/2/1 / RGB definition – 0/101/172)
Orange (CMYK definition - 0/71/88/0 / RGB definition – 243/110/53)
Pink (CMYK definition - 0/100/50/0 / RGB definition – 237/20/90)
Yellow (CMYK definition - 1/29/94/0 / RGB definition – 249/185/40)
Green (CMYK definition - 77/10/96/2 / RGB definition – 59/162/75)
Magenta (CMYK definition - 65/98/28/25 / RGB definition – 97/33/94)


In order to have consistency throughout the journal, the publishers reserve the right to re-draw figures, where necessary, with the appropriate colours from the palette. Authors will have an opportunity to correct inappropriate changes at the proof correction stage.

For useful information on preparing your figures for publication, go to http://cpc.cadmus.com/da/index.jsp . Figures will not be relettered by the publisher. The journal reserves the right to reduce the size of illustrative material. Any photomicrographs, electron micrographs or radiographs must be of high quality. Wherever possible, photographs should fit within the area of 169 x 235 mm (full page) or within the column width of 82 mm. Photomicrographs should provide details of staining technique and a scale bar. Patients shown in photographs should have their identity concealed or should have given their written consent to publication.

Image acquisition and analysis

If primary experimental data are presented in the form of a computer-generated image any editing must be described in detail. A linear (rather than sigmoidal) relationship between signal and image intensity is assumed. Unless stated otherwise, it will be assumed that all images are unedited.

Inappropriate manipulation of images to highlight desired results is not allowed. Please adhere to the following guidelines to accurately present data:
• No specific feature within an image may be enhanced, obscured, moved, removed, or introduced.
• The grouping of images from different parts of the same gel, or from different gels, fields, or exposures (ie, the creation of a "composite image") must be made absolutely explicit by the arrangement of the figure (ie, using dividing lines) and explained in the figure legend.
• Adjustments of brightness, contrast, or colour balance are acceptable if they are applied to the whole image and as long as they do not obscure, eliminate, or misrepresent any information present in the original, including the background.
• Non-linear adjustments (eg, changes to gamma settings) must be disclosed in the figure legend.
• Alteration of brightness or contrast that results in the disappearance of any features in a gel (either bands or cosmetic blemishes) or similar alterations in other experimental images is strictly forbidden.

Authors should retain unprocessed images and metadata files, as the Journal may request them during manuscript evaluation, and/or after publication should there be a query relating to a specific figure. Files that have been adjusted in any way should be saved separately from the originals, in a non-compressed format. Compressed formats, such as JPG, should only be used for presentation of final figures, when requested, to keep file sizes small for electronic transmission. The Journal reserves the right to use image analysis software on any submitted image.

Informed consent

Patient’s identity must be removed in all figures (i.e., x-rays, MRIs, charts, photographs, etc.). Written informed consent is required from any potentially identifiable patient or legal representative, and should be presented in either the Methods section or the Acknowledgements.

ABBREVIATIONS

Authors should not use abbreviations in headings and figure legends should be comprehensive without extensive repetition of the Subjects and Methods section. Authors are advised to refrain from excessive use of uncommon abbreviations, particularly to describe groups of patients or experimental animals.

TRADE NAMES

Non-proprietary (generic) names of products should be used. If a brand name for a drug is used, the British or International non-proprietary (approved) name should be given. The source of any new or experimental preparation should also be given.

REFERENCES

The references should be numbered in the order in which they appear in the text.

At the end of the article the full list of references should give the name and initials of all authors unless there are more than six, when only the first three should be given followed by et al. The authors' names should be followed by the title of the article, the title of the Journal abbreviated according to the style of Index Medicus, the year of publication, the volume number and the first and last page numbers. References to books should give the title of the book, which should be followed by the place of publication, the publisher, the year and the relevant pages.

EXAMPLES
1. Madaio MP. Renal biopsy. Kidney Int 1990; 38: 529-543

Books:
2. Roberts NK. The cardiac conducting system and the His bundle electrogram. Appleton-Century-Crofts, New York, NY: 1981; 49-56

Chapters:
3. Rycroft RJG, Calnan CD. Facial rashes among visual display unit (VDU) operators. In: Pearce BG, ed. Health hazards of VDUs. Wiley, London, UK: 1984; 13-15

Note: In the online version of CKJ , there are automatic links from the reference section of each article to Medline. This is a useful feature for readers, but is only possible if the references are accurate. It is the responsibility of the author to ensure the accuracy of the references in the submitted article. Downloading references direct from Medline is highly recommended.

SUPPLEMENTARY MATERIAL

Supporting material that is not essential for inclusion in the full text of the manuscript, but would nevertheless benefit the reader, can be made available by the publisher as online-only content, linked to the online manuscript. There is no charge for the publication of online-only supplementary data/tables/figures. Such material should not be essential to understanding the conclusions of the paper, but should contain data that is additional or complementary and directly relevant to the article content. Such information might include more detailed methods, extended data sets/data analysis, or additional figures (including colour).

All text and figures must be provided in suitable electronic formats (instructions for the preparation of Supplementary material can be viewed here). All material to be considered as Supplementary material must be submitted at the same time as the main manuscript for peer review. It cannot be altered or replaced after the paper has been accepted for publication. Please indicate clearly the material intended as Supplementary material upon submission. Also ensure that the Supplementary material is referred to in the main manuscript where necessary.

COLOUR ILLUSTRATIONS

As of January 2015 Clinical Kidney Journal (CKJ) will be a fully Open Access journal, the article processing charge (APC), including charges for colour illustrations, will be waived for all papers published during 2015 and 2016.

LANGUAGE EDITING

Particularly if English is not your first language, before submitting your manuscript you may wish to have it edited for language. This is not a mandatory step, but may help to ensure that the academic content of your paper is fully understood by journal editors and reviewers. Language editing does not guarantee that your manuscript will be accepted for publication. If you would like information about such services please click here . There are other specialist language editing companies that offer similar services and you can also use any of these. Authors are liable for all costs associated with such services.

COPYRIGHT

Please note that the journal now encourages authors to complete their copyright licence to publish form online

Upon receipt of accepted manuscripts at Oxford Journals authors will be invited to complete an online copyright licence to publish form.

Please note that by submitting an article for publication you confirm that you are the corresponding/submitting author and that Oxford University Press ("OUP") may retain your email address for the purpose of communicating with you about the article. You agree to notify OUP immediately if your details change. If your article is accepted for publication OUP will contact you using the email address you have used in the registration process. Please note that OUP does not retain copies of rejected articles.

It is a condition of publication in the Journal that authors grant an exclusive licence to the Journal, published by Oxford University Press on behalf of the European Renal Association-European Dialysis and Transplant Association. This ensures that requests from third parties to reproduce articles are handled efficiently and consistently and will also allow the article to be as widely disseminated as possible. In assigning the licence, authors may use their own material in other publications provided that the Journal is acknowledged as the original place of publication and Oxford University Press is notified in writing and in advance.

If any tables, illustrations or photomicrographs have been published elsewhere, written consent for re-publication must be obtained by the author from the copyright holder and the author(s) of the original article, such permission being detailed in the cover letter.

THIRD-PARTY CONTENT IN OPEN ACCESS PAPERS

If you will be publishing your paper under an Open Access licence but it contains material for which you do not have Open Access re-use permissions, please state this clearly by supplying the following credit line alongside the material:

Title of content
Author, Original publication, year of original publication, by permission of [rights holder]

This image/content is not covered by the terms of the Creative Commons licence of this publication. For permission to reuse, please contact the rights holder.

TRANSPARENCY DECLARATION

All authors must make a formal declaration at the time of submission indicating any potential conflict of interest. This is a condition of publication and failure to do so will delay the review process. Such declarations might include, but are not limited to, shareholding in or receipt of a grant, travel award or consultancy fee from a company whose product features in the submitted manuscript or a company that manufactures a competing product.

You will be required to provide this information during the online submission process.

In addition , in the interests of openness, ALL papers submitted to CKJ MUST include a ‘Transparency declarations’ section (which should appear at the end of the paper, before the ‘References’ section) within the article. We suggest authors concentrate on transparency declarations (i.e. conflicts of interest) of a financial nature, although relevant non-financial disclosures can also be made.

Authors should either include appropriate declarations or state ‘None to declare’. Importantly, the declarations should be kept as concise as possible, should avoid giving financial details (e.g. sums received, numbers of shares owned etc.), and should be restricted to declarations that are specific to the paper in question. Authors will of course need to consider whether or not the transparency declarations need to be amended when revisions are submitted.

Please click here to consult the COPE guidelines on conflict of interest. The editors’ declarations of interest statements can also be viewed online.

CROSSCHECK

The CKJ Editorial teams reserve the right to use CrossCheck. CrossCheck is an initiative started by CrossRef to help its members actively engage in efforts to prevent scholarly and professional plagiarism.

By submitting your manuscript to the journal it is understood that this it is an original manuscript and is unpublished work and is not under consideration elsewhere. Plagiarism, including duplicate publication of the author’s own work, in whole or in part without proper citation is not tolerated by the journal.

PREPARATION OF MANUSCRIPTS TO BE PUBLISHED IN CKJ

Full information for all article types is detailed below.

Editorial Comments

Word count: maximum 3000, with an abstract of up to 200 words. Authors may include 2 figures or tables.
Maximum number of authors: 3
Keywords: 5
References: maximum 50 including the reference of the paper or papers that are commented upon. The authors and title of papers to be published in the same issue (of CKJ ) may be followed by xxx, these will be populated by the journal once known.

These editorials are usually solicited by the editors but may also be submitted without invitation on topics published in CKJ ; they should be topical and highly focused.

CKJ Reviews

Word count: maximum 4000, excluding abstract (up to 250 words) and references.
Authors should include at least 4 figures or tables.
Maximum number of authors: 10
Keywords: maximum of 7
References: no maximum

These reviews are usually solicited by the editors and are comprehensive analyses of specific topics in nephrology. Potential authors may suggest topics for Editorial Reviews for consideration by the Editors.

CKJ Reviews Series - CKD Hotspots around the World:

To propose a CKD hotspot to be reviewed in the CKD hotspots series of CKJ, please send an e-mail with the subject “CKD hotspots” to aortiz@fjd.es and also to caroline.vinck@era-edta.org , indicating what the
proposed hotspot is, its geographical location, why you think this hotspot should be featured and references or epidemiological data supporting the existence of the hotspot.

Original Articles

Word count: maximum 3000, excluding abstract (up to 250 words) but excluding references, tables and figures.
Authors may include figures or tables.
Maximum number of authors: 10
Keywords: maximum 7
References: maximum 50

The order of original articles should be as follows:

1. Title page including the title (please bear in mind that we prefer a title to be concise yet eye-catching) and details of all authors, including first or given name, and affiliation.
2. (On a separate page) an abstract of ~250 words, which should consist of four sections: 'Background', 'Methods', 'Results' and 'Conclusions'. They should briefly describe, respectively, the problems being addressed in this study, how the study was performed, the salient results and what the authors concluded from the study.
3. Keywords: not more than 7, in alphabetical order, characterizing the scope of the paper, the principal materials, and main subject of work.
4. On a new page: Introduction, Subjects and Methods, Results, Discussion, Acknowledgements, References, Table, Legends to figure and Figure. All pages should be numbered consecutively commencing with the title page. Headings (Introduction, Subjects and Methods etc) should be placed on separate lines.

Any statistical method must be detailed in the Subjects and Methods section, and any not in common use should be described fully or supported by references.

Exceptional Case Reports

Word count: maximum 750 words, with an abstract of up to 100 words.
Maximum number of authors: 6
Maximum 1 figure or table
Keywords: maximum 7
References: maximum 5

Failure to meet these requirements upon submission will result in the submission not being processed.

The order of Exceptional Case papers should be as follows:

1. Title page giving details of all authors, including first or given name, and affiliation.
2. On a separate page an abstract of 100 words summarising the case and its importance.
3. Keywords: not more than 5, in alphabetical order, characterizing the case.
4. On a new page: Background, Case Report(s), Discussion, Acknowledgements, References, Tables, Legends to figures and Figures. All pages should be numbered consecutively commencing with the title page. Headings (Introduction; Case report(s), etc) should be placed on separate lines. It is important that authors number their pages and lines prior to submission as reviewers will refer to particular pages/lines when providing their comments on the manuscript.

Exceptional cases should provide unique insight into the pathophysiology of disease or describe novel clinical observations. Descriptions of rare diseases will only be considered if they provide new information about the condition.

LICENCES AND CHARGES

We are pleased to announce that fees will continue to be waived. There will be no charge to authors for open access publication in 2016, with the exception of those who must publish under a CC BY licence in order to comply with funding body mandates. There will be no cost of publication for authors (with the exception of articles publishing under a CC BY licence for which there will be a charge with discounted rates for ERA-EDTA members).

LICENCES

CKJ offers the following licences:

• Creative Commons Attribution licence (CC BY)
• Creative Commons Non-Commercial licence (CC BY-NC)
• Crown Copyright Open Access Agreement
• Open US Government Agreement

CHARGES

For papers accepted after 20th October 2014 charges for CC BY-NC, Crown Copyright Open Access, and Open US Gov Agreement will be waived.

Charges for CC BY will not be waived. Please click here for more information about the Creative Commons licences.

You can pay the CC BY charge using our Author Services site. This will enable you to pay online with a credit/debit card, or request an invoice by email or post. The open access charges for CC BY are:

• Regular charge: £1050/$1700/€1400
• Society member charge: £550/$850/€700
• Reduced Rate Developing country charge*: £525/$850/€700
• Free Developing country charge *: £0/$0/€0

*Visit our developing countries page for a list of qualifying countries.

OFFPRINTS

Authors receive electronic access to their paper free of charge.

AUTHOR SELF-ARCHIVING/PUBLIC ACCESS POLICY

For information about this journal's policy, please visit our Author Self-Archiving policy page .

EDITORIAL ENQUIRIES

Professor Alberto Ortiz
IIS-Fundacion Jimenez Diaz,
School of Medicine,
Universidad Autonoma de Madrid
Av Reyes Catolicos 2
28040 Madrid
Spain
Email


For all general enquiries concerning submissions to CKJ , please contact the CKJ Editorial Office

PRODUCTION ENQUIRIES

CKJ Production Editor
Journals Production
Oxford University Press
Great Clarendon Street
Oxford OX2 6DP, UK
Tel: +44 1865 354957
Fax: +44 1865 353798
Email: ckj@oup.com

CROSSREF FUNDING DATA REGISTRY

In order to meet your funding requirements authors are required to name their funding sources, or state if there are none, during the submission process. For further information on this process or to find out more about the CHORUS initiative please click here .

DISCLAIMER

Drug Disclaimer
The mention of trade names, commercial products or organizations, and the inclusion of advertisements in ckj do not imply endorsement by the Society, the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated. The editors and publishers have taken all reasonable precautions to verify drug names and doses, the results of experimental work and clinical findings published in ckj . The ultimate responsibility for the use and dosage of drugs mentioned in ckj and in the interpretation of published material lies with the medical practitioner, and the editors and publishers cannot accept liability for damages arising from any errors or omissions in ckj . Please inform the editors of any errors.

Material Disclaimer
The opinions expressed in ckj those of the authors and contributors, and do not necessarily reflect those of the Society the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated.

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Subscribe Now